Published in J Clin Rheumatol on December 01, 2012
Enalapril Maleate on Arterial Stiffness in Rheumatoid Arthritis. | NCT03667131
Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosclerosis. Circ Res (2014) 1.93
Arterial stiffness and cardiovascular therapy. Biomed Res Int (2014) 1.03
Non-invasive imaging of vascular inflammation. Front Immunol (2014) 0.81
Regulation of Adaptive Immunity in Health and Disease by Cholesterol Metabolism. Curr Allergy Asthma Rep (2015) 0.81
Is There Any Relationship between Joint Destruction and Carotid Intima-media Thickness in Patients with Rheumatoid Arthritis? J Phys Ther Sci (2014) 0.79
The Malaria-High Blood Pressure Hypothesis. Circ Res (2016) 0.79
Why are kids with lupus at an increased risk of cardiovascular disease? Pediatr Nephrol (2015) 0.78
GDF15(MIC1) H6D Polymorphism Does Not Influence Cardiovascular Disease in a Latin American Population with Rheumatoid Arthritis. J Immunol Res (2015) 0.77
Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review. Rheumatol Int (2016) 0.77
Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature. J Med Case Rep (2015) 0.76
Insight into the Endocrine System and the Immune System: A Review of the Inflammatory Role of Prolactin in Rheumatoid Arthritis and Psoriatic Arthritis. Front Immunol (2017) 0.75
Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study. Lancet (2012) 6.29
Exercise-induced pulse wave velocity changes in untreated patients with essential hypertension: the effect of an angiotensin receptor antagonist. J Clin Hypertens (Greenwich) (2014) 2.61
Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet (2008) 2.53
Left ventricular hypertrophy as a determinant of renal outcome in patients with high cardiovascular risk. J Hypertens (2010) 2.14
A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol (2006) 2.13
Exercise capacity and mortality in older men: a 20-year follow-up study. Circulation (2010) 1.54
Is it safe to readminister tumor necrosis factor alpha antagonists following tuberculosis flare? Arthritis Rheum (2008) 1.51
Hypertension associated with rhabdomyolysis. J Clin Hypertens (Greenwich) (2007) 1.47
Tissue factor-thrombin signaling enhances the fibrotic activity of myofibroblasts in systemic sclerosis through up-regulation of endothelin receptor A. Arthritis Rheum (2011) 1.46
Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis. Blood (2010) 1.44
Platelets interplay between pneumonia and cardiovascular events: establishing a link? J Am Coll Cardiol (2015) 1.28
BMI-mortality paradox and fitness in African American and Caucasian men with type 2 diabetes. Diabetes Care (2012) 1.14
Hyperuricemia as a risk factor for cardiovascular disease. Expert Rev Cardiovasc Ther (2014) 1.11
Platelet activation during exercise is not attenuated by inhibition of the renin-angiotensin system: the role of physical activity. J Hypertens (2013) 1.11
Exercise capacity and progression from prehypertension to hypertension. Hypertension (2012) 1.08
Cardiovascular risk in psoriatic arthritis: should we focus on hypertension and diabetes only? Clin Exp Rheumatol (2014) 1.08
Macro and microcirculation damage and incident hypertension: predictors of progression? J Hypertens (2014) 1.07
Does vitamin D really contribute to excess cardiovascular risk in rheumatoid arthritis? Comment on the article by Haque et al. Arthritis Care Res (Hoboken) (2013) 1.07
Exercise-induced platelet activation in essential hypertension: have we solved the puzzle? J Hypertens (2013) 1.06
The enigma of microvascular and macrovascular changes in mild essential hypertension. J Hypertens (2014) 1.06
Investigating the association between creatine kinase and failure of antihypertensive treatment: much to be thought of in the everyday clinical setting. J Hypertens (2013) 1.05
Sexual dysfunction: the 'prima ballerina' of hypertension-related quality-of-life complications. J Hypertens (2008) 1.03
Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis. Rheumatol Int (2009) 0.96
Masked hypertension in untreated and treated patients with diabetes mellitus: attractive but questionable interpretations. Hypertension (2013) 0.96
Autologous HSCT for systemic sclerosis. Lancet (2013) 0.96
Body mass index, exercise capacity, and mortality risk in male veterans with hypertension. Am J Hypertens (2012) 0.93
Intracerebral hemorrhage as the presenting feature of concurrent pheochromocytoma and paragangliomas. J Clin Hypertens (Greenwich) (2008) 0.92
Antihypertensive treatment and sexual dysfunction. Curr Hypertens Rep (2012) 0.91
Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med (2017) 0.91
Vascular disease in systemic lupus erythematosus. Autoimmune Dis (2012) 0.90
Renal sympathetic denervation: renal function concerns. Hypertension (2011) 0.90
Common secondary causes of resistant hypertension and rational for treatment. Int J Hypertens (2011) 0.89
Leiomyosarcoma of renal vein, initially resembling pheochromocytoma. Clin Exp Hypertens (2012) 0.88
Combined angiotensin inhibition in diabetic nephropathy. N Engl J Med (2014) 0.88
Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension: a perspective. J Hypertens (2012) 0.88
Exercise capacity and mortality in hypertensive men with and without additional risk factors. Hypertension (2009) 0.87
Effect of tobacco smoking and smoking cessation on plasma lipoproteins and associated major cardiovascular risk factors: a narrative review. Curr Med Res Opin (2013) 0.87
Exercise capacity and all-cause mortality in prehypertensive men. Am J Hypertens (2009) 0.86
Heart rate recovery, exercise capacity, and mortality risk in male veterans. Eur J Prev Cardiol (2011) 0.86
Surgical management of primary aldosteronism. not everything that shines is gold. Clin Exp Hypertens (2011) 0.85
Spontaneous urinoma: an unexpected cause of acute abdomen. Am J Emerg Med (2010) 0.85
Treatment of hypertension in the elderly. N Engl J Med (2008) 0.84
The multivalent activity of the tissue factor-thrombin pathway in thrombotic and non-thrombotic disorders as a target for therapeutic intervention. Expert Opin Ther Targets (2010) 0.83
Stenting for renal-artery stenosis. N Engl J Med (2014) 0.82
The interaction of vasoactive substances during exercise modulates platelet aggregation in hypertension and coronary artery disease. BMC Cardiovasc Disord (2008) 0.82
Atherosclerosis and infection: is the jury still not in? Future Microbiol (2012) 0.82
Benefits from treatment and control of patients with resistant hypertension. Int J Hypertens (2010) 0.82
Hypertension and sexual dysfunction: time to act. J Hypertens (2011) 0.81
Renal nerve ablation for resistant hypertension: how did we get here, present status, and future directions. Circulation (2014) 0.81
Capillary rarefaction as an index for the microvascular assessment of hypertensive patients. Curr Hypertens Rep (2015) 0.81
Heart rate at rest, exercise capacity, and mortality risk in veterans. Am J Cardiol (2013) 0.81
Prevalence, awareness, treatment and control of hypertension in an elderly population in Greece. Rural Remote Health (2010) 0.81
Pheochromocytoma presenting as diabetic ketoacidosis. J Diabetes Complications (2008) 0.80
Association between mental health disorders and sexual dysfunction in patients suffering from rheumatic diseases. J Sex Med (2014) 0.80
Halting arterial aging in patients with cardiovascular disease: hypolipidemic and antihypertensive therapy. Curr Pharm Des (2014) 0.79
Upregulation of VEGF expression is associated with accumulation of HIF-1α in the skin of naïve scleroderma patients. Mod Rheumatol (2012) 0.79
Carotid baroreceptor stimulation for the treatment of resistant hypertension. Int J Hypertens (2011) 0.79
A graded association of exercise capacity and all-cause mortality in males with high-normal blood pressure. Blood Press (2009) 0.79
Association between cardiotrophin 1 levels and central blood pressure in untreated patients with essential hypertension. Am J Hypertens (2014) 0.79
Treatment of postmenopausal women with osteoporosis with PTH(1-84) for 36 months: treatment extension study. Curr Med Res Opin (2010) 0.78
Anti-TNF-alpha-induced psoriasis: case report of an unusual adverse event. Int J Dermatol (2006) 0.78
Response to rituximab and timeframe to relapse in rheumatoid arthritis patients: association with B-cell markers. Mol Diagn Ther (2010) 0.78
Capillaroscopy as a screening test for clinical antiphospholipid syndrome. Eur J Intern Med (2011) 0.77
Antiplatelet treatment in essential hypertension: where do we stand? Curr Hypertens Rep (2015) 0.77
PDE-5 inhibitors: clinical points. Curr Drug Targets (2015) 0.77
Hypertriglyceridaemic waist phenotype criteria and prevalent metabolic triad in women. Diabetes Metab Res Rev (2008) 0.77
Platelet activation in essential hypertension during exercise: pre- and post-treatment changes with an angiotensin II receptor blocker. Am J Hypertens (2013) 0.76
Lipids, Statins and Heart Failure: An Update. Curr Pharm Des (2016) 0.75
Tumor necrosis factor antagonist-associated neutropenia: comment on the article by Hastings et al. Arthritis Care Res (Hoboken) (2010) 0.75
Telmisartan for prevention of cardiovascular events. N Engl J Med (2009) 0.75
Evaluating the true prevalence of resistant hypertension. Hypertension (2011) 0.75
Reply to: Seeing the forest, but not the trees: pertinent considerations for examining acute changes in pulse wave velocity in response to pharmaceutical interventions and exercise. J Clin Hypertens (Greenwich) (2014) 0.75
Retinopathy assessment in hypertension is still puzzling. Am J Hypertens (2012) 0.75
Effects of antihypertensive therapy on female sexual dysfunction: clinically meaningful? J Hypertens (2012) 0.75
Letter by Triantafyllou et al regarding article, "Mild retinopathy is a risk factor for cardiovascular mortality in Japanese with and without hypertension: the Ibaraki Prefectural Health Study". Circulation (2012) 0.75
Statin and exercise prescription - Authors' reply. Lancet (2013) 0.75
Prehypertension and the cardiometabolic syndrome: targeting several risk factors to achieve maximum benefit. Expert Rev Cardiovasc Ther (2014) 0.75
Clarifying the role of preoperative α-blockade in pheochromocytoma? J Hypertens (2012) 0.75
Effect of renal sympathetic denervation on short-term blood pressure variability in resistant hypertension: a meta-analysis. J Hypertens (2017) 0.75
Absence of human bocavirus in atherosclerotic plaques of carotid arteries by real-time polymerase chain reaction. Scand J Infect Dis (2010) 0.75
Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study. Am J Nephrol (2016) 0.75
Novel drugs for hypertension and heart failure: struggling for a place under the sun. Curr Pharm Des (2017) 0.75
Clinical images: iloprost-induced vascular remodeling. Arthritis Rheum (2007) 0.75
The effect of proprotein convertase subtilisin-kexin type 9 and its inhibition on glucose metabolism and cardiovascular risk. We should do better the second time after statins. Curr Pharm Des (2017) 0.75